Nova Nordisk

Nova Nordisk

Nova Nordisk

Diabetes and Protein Technologies

Novo Nordisk has been a world leader in diabetes care since 1923 and continues to pioneer the development of novel treatments for this serious condition. We are constantly striving to improve the lives of people with diabetes by finding better methods of diabetes treatment and prevention. We master all aspects of protein and peptide drug development and target our efforts on improving blood sugar control, which is essential for preventing and delaying diabetes-related complications. Novo Nordisk R&D focuses on new insulin and GLP-1 analogues, other new treatments for diabetes, including its microvascular complications, obesity, and on protein technologies and delivery systems. Our research and development into the oral delivery of protein and peptide therapeutics promises to bring people with diabetes new treatment options for the safe and effective management of their disease. We develop and market pharmaceutical products and services that make a significant difference to patients, the medical profession, and society. We have a proven track record and the capabilities to succeed.

Compounds

Insulin and GLP-1 receptor peptide-agonists:

  • Insulins and GLP-1s with novel therapeutic properties
  • Optimized for oral delivery
  • Modified duration of action
  • Improved side-effect profile

Therapeutic proteins and peptides affecting:

  • Glucose regulation with additional benefits
  • Insulin secretion
  • Insulin resistance
  • Beta-cell mass
  • Obesity
  • Diabetes late complications
  • Inflammation related to diabetes and obesity
  • Prevention/progression of diabetes

Technologies:

Protein and peptide technologies:

  • Expression
  • Modification
  • Production

Formulation and drug delivery technologies for proteins and peptides:

  • Liquid
  • Oral
  • Sustained/triggered release

(3BL Media / theCSRfeed) BAGSVÆRD, Denmark - February 7, 2012 - Novo Nordisk’s eighth annual integrated report, now online, reports on the company’s very positive financial, social and environmental performance for 2011. Download the Annual Report 2011 at annualreport2011.novonordisk.com.

  • Sales increased by 11% (in local currencies) and by 9% in Danish kroner compared to 2010.

  • Operating profit increased by 22% (in local currencies) and 18% in Danish kroner compared to 2010.

  • Significant clinical development progress was made during the year, including regulatory filing for two ultra-long-acting insulins, Degludec and DegludecPlus.

  • More than 835,000 healthcare providers were trained by Novo Nordisk or Novo Nordisk sponsored programmes, an increase of 123% compared to 2010.

  • Diversity in senior management teams increased to 62% at the end of 2011, compared to 54% at the end of 2010.

  • CO2 emissions from production fell by 2% compared to 2010, for an absolute reduction of 56% compared to 2004 levels. 

Novo Nordisk’s 2011 Annual Report includes a detailed account of 2011 accomplishments, an outlook for 2012, and an overview of the company’s management approach, corporate strategy and business segments.  It features consolidated financial, social and environmental statements.
 
The Annual Report 2011 includes updated information for financial and environmental targets.
 
Novo Nordisk’s integrated reporting
Novo Nordisk manages its business using the Triple Bottom Line principle to ensure that decision-making balances profitability with longer-term societal interests. Material and business-critical information is reported in the Annual Report.  The company reports additional information for specific stakeholder groups at annualreport2011.novonordisk.com. Novo Nordisk values feedback and welcomes questions or comments about its reporting and performance at annualreport@novonordisk.com.
 
About Novo Nordisk
Novo Nordisk is a global healthcare company with nearly 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 32,000 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
 
Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance. In 2012, Novo Nordisk receive top ranking on Corporate Knight’s list of Global 100 Most Sustainable Corporations. Novo Nordisk is listed in the 2010/2011 Dow Jones Sustainability Indices with agold class rating. For more information, visit novonordisk.com/sustainability. 
 

NOVO20871


Posted by Admin on February 10, 2012 - 9:43 am Posted in nordstrom cedar rapids
  • Nova Nordisk

    Nova Nordisk

    Nova Nordisk

  • Search